StreetInsider.com News Articles

Form 8-K Lipocine Inc. For: Oct 20

Tue, 20 Oct 2026 07:47:00 -0400

si-local-file:///var/storage/secattach/20261020/27206684.html

Lipocine stock surges 30% on Health Canada drug approval

Wed, 07 Oct 2026 08:56:49 -0400

Investing.com -- Lipocine Inc (NASDAQ:LPCN) shares rose 30% in premarket trading Wednesday after Health Canada approved the company's oral testosterone drug TLANDO.

The approval, announced through Lipocine's licensing partner Verity Pharmaceuticals Inc., allows TLANDO (testosterone undecanoate) capsules to be marketed for testosterone replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone. Verity Pharma holds exclusive commercial rights to TLANDO in North America and plans to launch the drug in the Canadian market by the end of 2026.

TLANDO is designed as an oral alternative to existing testosterone replacement therapies, which are primarily

Lipocine stock surges 30% on Health Canada drug approval

Wed, 07 Oct 2026 08:56:49 -0400

Investing.com -- Lipocine Inc (NASDAQ:LPCN) shares rose 30% in premarket trading Wednesday after Health Canada approved the company's oral testosterone drug TLANDO.

TLANDO is designed as an oral alternative to existing testosterone replacement therapies, which are primarily

Health Canada approves Lipocine's oral testosterone drug TLANDO

Wed, 07 Oct 2026 08:01:35 -0400

Lipocine Inc. (NASDAQ: LPCN) announced that Health Canada has approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males with male hypogonadism, a condition involving a deficiency or absence of endogenous testosterone.

The approval was obtained through Verity Pharmaceuticals Inc., Lipocine's licensing partner, which holds exclusive commercial rights to TLANDO in North America. Verity Pharma plans to launch the drug in the Canadian market by the end of 2026.

Lipocine and Verity Pharma entered into an exclusive license agreement in January 2024, under which Verity Pharma assumed responsibility for regulatory and commercialization obligations in the United States and Canada.

TLANDO is

Health Canada approves Lipocine's oral testosterone drug TLANDO

Wed, 07 Oct 2026 08:01:35 -0400

TLANDO is

Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy

Wed, 07 Oct 2026 08:00:00 -0400

SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity Pharmaceuticals Inc (Verity Pharma), Health Canada has approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males for the conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism). Verity

Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy

Wed, 07 Oct 2026 08:00:00 -0400

Health Canada approves Tlando oral testosterone therapy from Lipocine

Wed, 07 Oct 2026 06:13:57 -0400

Health Canada has approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy (TRT) in adult males with hypogonadism, according to a statement from Lipocine Inc. (NASDAQ: LPCN).

TLANDO is an oral capsule that uses a fixed dosing regimen and does not require dose titration. Lipocine and Verity Pharma entered into an exclusive license agreement in January 2024, under which Verity Pharma assumed regulatory and commercialization responsibilities for

Health Canada approves Tlando oral testosterone therapy from Lipocine

Wed, 07 Oct 2026 06:13:57 -0400

Form 8-K Lipocine Inc. For: Oct 07

Wed, 07 Oct 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20261007/27157564.html

Form 4 Lipocine Inc. For: Sep 29 Filed by: Higuchi John W.

Thu, 01 Oct 2026 20:28:00 -0400

si-local-file:///var/storage/secattach/20261001/27137723.html

Form 4 Lipocine Inc. For: Sep 28 Filed by: Higuchi John W.

Wed, 30 Sep 2026 20:39:00 -0400

si-local-file:///var/storage/secattach/20260930/27129907.html

H.C. Wainwright Reiterates Neutral Rating on Lipocine Inc (LPCN)

Tue, 22 Sep 2026 07:35:43 -0400

H.C. Wainwright analyst Yi Chen reiterated a Neutral rating and $4.00 price target on Lipocine Inc (NASDAQ: LPCN).

The analyst commented: "Last week, Lipocine announced the initiation of the Phase 3 BLOOM trial of LPCN1154 for the treatment of severe postpartum depression (PPD). Management expects to dose the first participant in early 4Q26. As a reminder, LPCN 1154 is an oral brexanolone being developed as a 48-hour at-home treatment for rapid symptom relief. Though the prior Phase 3 trial did not meet its primary endpoint in the full analysis set, exploratory post hoc analyses identified anomalies concentrated at one clinical site.

Form 8-K Lipocine Inc. For: Sep 16

Wed, 16 Sep 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260916/27070791.html

Lipocine starts new Phase 3 trial for postpartum depression drug

Mon, 14 Sep 2026 08:00:56 -0400

Lipocine Inc. (NASDAQ: LPCN) announced the initiation of BLOOM, a Phase 3 clinical study evaluating LPCN 1154, an oral formulation of brexanolone, as a treatment for postpartum depression (PPD), according to a company press release dated Sept. 14, 2026.

The placebo-controlled outpatient study plans to enroll approximately 120 participants with severe PPD. First participant dosing is expected in early Q4 2026. LPCN 1154 is being developed as a 48-hour, at-home oral treatment. The study's primary efficacy measure is the change from baseline in the 17-item Hamilton Depression Rating Scale (HAM-D17) total score at 60 hours post-dosing initiation.

The new study follows a

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Mon, 14 Sep 2026 08:00:00 -0400

Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial
Approximately 120 participants with severe postpartum depression (PPD) planned; first participant dosing expected in early Q4 2026

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Mon, 14 Sep 2026 08:00:00 -0400

Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial
Approximately 120 participants with severe postpartum depression (PPD) planned; first participant dosing expected in early Q4 2026

Form 8-K Lipocine Inc. For: Sep 14

Mon, 14 Sep 2026 06:15:00 -0400

si-local-file:///var/storage/secattach/20260914/27054987.html

Form 8-K Lipocine Inc. For: Sep 08

Fri, 11 Sep 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260911/27050503.html

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 08:00:00 -0400

SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 08:00:00 -0400

Form 8-K Lipocine Inc. For: Sep 10

Thu, 10 Sep 2026 06:14:00 -0400

si-local-file:///var/storage/secattach/20260910/27044716.html

Form 8-K/A Lipocine Inc. For: Aug 03

Fri, 21 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260821/26961790.html

Form 8-K/A Lipocine Inc. For: Aug 03

Fri, 21 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260821/26961790.html

Form SCHEDULE 13G/A Lipocine Inc. Filed by: Squadron Capital Management LLC

Fri, 14 Aug 2026 13:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26928158.html